Carregant...
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/207183
The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Chemotherapy often generates intratumoral senescent cancer cells that strongly modify the tumor microenvironment, favoring immunosuppression and tumor growth. We discovered, through an unbiased proteomics screen, that the immune checkpoint inhibitor programmed cell death 1 ligand 2 (PD-L2) is highly upregulated upon induction of senescence in different types of cancer cells. PD-L2 is not required for cells to undergo senescence, but it is critical for senescent cells to evade the immune system and persist intratumorally. Indeed, after chemotherapy, PD-L2-deficient senescent cancer cells are rapidly eliminated and tumors do not produce the senescence-associated chemokines CXCL1 and CXCL2. Accordingly, PD-L2-deficient pancreatic tumors fail to recruit myeloid-derived suppressor cells and undergo regression driven by CD8 T cells after chemotherapy. Finally, antibody-mediated blockade of PD-L2 strongly synergizes with chemotherapy causing remission of mammary tumors in mice. The combination of chemotherapy with anti-PD-L2 provides a therapeutic strategy that exploits vulnerabilities arising from therapy-induced senescence. © 2024, The Author(s).
Matèries
Matèries (anglès)
Citació
Citació
CHAIB, S., LÓPEZ DOMÍNGUEZ, J. a., LALINDE GUTIÉRREZ, M., PRATS, Neus, MARIN, I., BOIX, O., GARCIA GARIJO, A., MEYER, K., MUÑOZ, M. i., AGUILERA, M., MATEO, L., STEPHAN OTTO ATTOLINI, C., LLANOS, S., PÉREZ RAMOS, S., ESCORIHUELA, M., AL SHAHROUR, F., CASH, T. p., TCHKONIA, T., KIRKLAND, J. l., ABAD, María, GROS, A., ARRIBAS, J., SERRANO, M.. The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2. _Nature Cancer_. 2024. [consulta: 20 de gener de 2026]. ISSN: 2662-1347. [Disponible a: https://hdl.handle.net/2445/207183]